2017 Annual Meeting of the European Association for the Study of the Liver*

April 19-23, 2017; Amsterdam, The Netherlands
Review Capsule Summaries, download slides, and listen to audio commentary from an expert-led Webinar covering critical studies from Amsterdam.



Glecaprevir/pibrentasvir was effective in both treatment-naive and treatment-experienced patients with no treatment-related serious adverse events or discontinuations due to adverse events.

Released: April 21, 2017

The SVR12 rate for 8 weeks of glecaprevir/pibrentasvir was noninferior to 12 weeks, which was noninferior to the rate achieved with standard-of-care sofosbuvir plus daclatasvir for 12 weeks.

Released: April 24, 2017

Ribavirin-free regimen noninferior to current standard-of-care DAA regimens and well tolerated in this challenging-to-treat patient population.

Released: April 25, 2017

12-weeks of NGM282 resulted in normalization of liver fat content and serum ALT levels in one third of treated patients, as well as improvements in other key biomarkers of NASH and fibrosis.

Released: April 25, 2017

Higher rates of ALT normalization and improved bone and renal safety markers with TAF vs TDF.

Released: April 25, 2017

Predictors of delisting include MELD score at the start of DAA therapy and the magnitude of change in MELD score after 12 weeks of treatment.

Released: April 23, 2017

Biomarker and histologic improvements were greater following treatment with selonsertib as compared with treatment with the humanized monoclonal antibody simtuzumab, which is designed to treat fibrosis.

Released: April 22, 2017

Treatment with velpatasvir/sofosbuvir regimens yielded 100% SVR rates, whereas daclatasvir plus sofosbuvir regimens yielded 92% to 100% SVR rates.

Released: April 23, 2017

100% SVR12 rates observed in patients who previously failed NS3/4A PI regimens; lowest SVR12 rates of 79% to 81% observed in patients who failed both NS3/4A PI and NS5A inhibitor regimens.

Released: April 25, 2017

Novel fixed-dose combination regimen effective in both cirrhotic and noncirrhotic patients with no serious drug-related adverse events or toxicity-driven discontinuations.

Released: April 24, 2017
Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

Educational grant provided by:
Gilead Sciences
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?